trimethoprim has been researched along with Epidermolysis Bullosa Dystrophica in 1 studies
Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.
trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.
Epidermolysis Bullosa Dystrophica: Form of epidermolysis bullosa characterized by atrophy of blistered areas, severe scarring, and nail changes. It is most often present at birth or in early infancy and occurs in both autosomal dominant and recessive forms. All forms of dystrophic epidermolysis bullosa result from mutations in COLLAGEN TYPE VII, a major component fibrils of BASEMENT MEMBRANE and EPIDERMIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lara-Corrales, I | 1 |
| Parkin, PC | 1 |
| Stephens, D | 1 |
| Hamilton, J | 1 |
| Koren, G | 1 |
| Weinstein, M | 1 |
| Sibbald, RG | 1 |
| Pope, E | 1 |
1 trial available for trimethoprim and Epidermolysis Bullosa Dystrophica
| Article | Year |
|---|---|
The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial.
Topics: Adolescent; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Drug Resistance, Micro | 2012 |